JO
PRLD icon

John Overdeck’s Prelude Therapeutics PRLD Stock Holding History

John Overdeck’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.29M Buy
993,369
+69,743
+8% +$304K ﹤0.01% 2098
2026
Q1 		$3.16M Buy
923,626
+134,931
+17% +$354K ﹤0.01% 2402
2025
Q4 		$2.29M Buy
788,695
+636,462
+418% +$1.07M ﹤0.01% 2334
2025
Q3 		$219K Sell
152,233
-2,744
-2% -$2.75K ﹤0.01% 3347
2025
Q2 		$125K Sell
154,977
-28,690
-16% -$24.8K ﹤0.01% 2977
2025
Q1 		$141K Sell
183,667
-48,172
-21% -$44.9K ﹤0.01% 2912
2024
Q4 		$296K Buy
231,839
+174,906
+307% +$232K ﹤0.01% 2741
2024
Q3 		$118K Buy
56,933
+13,798
+32% +$63.9K ﹤0.01% 2878
2024
Q2 		$164K Sell
43,135
-17,462
-29% -$71.1K ﹤0.01% 2765
2024
Q1 		$287K Buy
60,597
+2,313
+4% +$9K ﹤0.01% 2576
2023
Q4 		$249K Buy
58,284
+45,471
+355% +$138K ﹤0.01% 2758
2023
Q3 		$39.6K Sell
12,813
-26,477
-67% -$99.4K ﹤0.01% 2833
2023
Q2 		$177K Buy
39,290
+16,835
+75% +$101K ﹤0.01% 2668
2023
Q1 		$128K Sell
22,455
-29,443
-57% -$180K ﹤0.01% 2643
2022
Q4 		$313K Sell
51,898
-53,703
-51% -$344K ﹤0.01% 2222
2022
Q3 		$698K Sell
105,601
-118,235
-53% -$797K ﹤0.01% 1625
2022
Q2 		$1.17M Buy
223,836
+43,424
+24% +$221K ﹤0.01% 1478
2022
Q1 		$1.25M Sell
180,412
-102,362
-36% -$936K ﹤0.01% 1600
2021
Q4 		$3.52M Buy
+282,774
New +$4.6M 0.01% 1441
2021
Q3 		– Sell
-10,116
Closed -$290K – 4605
2021
Q2 		$290K Buy
+10,116
New +$360K ﹤0.01% 3538

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

John Overdeck's PRLD Position: Q2 2026 in Review

John Overdeck increased its Prelude Therapeutics (PRLD) stake by 7.6% in Q2 2026, buying an estimated $304K and bringing the position to 993,369 shares worth $5.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2098.

John Overdeck first reported a position in PRLD in Q2 2021 and has held it in 20 quarters since. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • John Overdeck held 993,369 shares of Prelude Therapeutics worth $5.29M as of Q2 2026.
  • John Overdeck bought 69,743 Prelude Therapeutics shares in Q2 2026, an estimated $304K.
  • Prelude Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2098 holding.
  • John Overdeck first reported a position in Prelude Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.